Literature DB >> 23422935

Synthesis of tacrine-lophine hybrids via one-pot four component reaction and biological evaluation as acetyl- and butyrylcholinesterase inhibitors.

Jessé Sobieski da Costa1, João Paulo Bizarro Lopes, Dennis Russowsky, Cesar Liberato Petzhold, Antonio César de Amorim Borges, Marco Antonio Ceschi, Eduardo Konrath, Cristiane Batassini, Paula Santana Lunardi, Carlos Alberto Saraiva Gonçalves.   

Abstract

A novel series of tacrine-lophine hybrids was synthesized and tested for their ability to inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 in the nanomolar concentration scale. The key step is the one-pot four component condensation reaction of 9-aminoalkylamino-1,2,3,4-tetrahydroacridines, benzil, different substituted aromatic aldehydes and NH4OAc, using InCl3 as the best catalyst. Tacrine-lophine hybrids were found to be potent and selective inhibitors of cholinesterases. As an extension of the four component approach to tetrasubstituted imidazoles, a new series of bis-(2,4,5-triphenyl-1H-imidazoles) or bis(n)-lophines was tested against AChE and BuChE.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23422935     DOI: 10.1016/j.ejmech.2013.01.029

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

Review 1.  Current advances in the synthesis and biological potencies of tri- and tetra-substituted 1H-imidazoles.

Authors:  Majid M Heravi; Mansoureh Daraie; Vahideh Zadsirjan
Journal:  Mol Divers       Date:  2015-04-12       Impact factor: 2.943

Review 2.  An overview on the synthesis of carbohydrate-based molecules with biological activity related to neurodegenerative diseases.

Authors:  João Paulo B Lopes; Luana Silva; Diogo S Lüdtke
Journal:  RSC Med Chem       Date:  2021-09-08

3.  A Platform for Screening Potential Anticholinesterase Fractions and Components Obtained from Anemarrhena asphodeloides Bge for Treating Alzheimer's Disease.

Authors:  Yu Sun; Ying Peng; Lin-Guang Li; Li-Wei Zheng; Dong-Ju Lin; Ling-Zhi Li; Shao-Jiang Song
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-17       Impact factor: 2.629

4.  Synthesis of thiazolidin-4-ones and thiazinan-4-ones from 1-(2-aminoethyl)pyrrolidine as acetylcholinesterase inhibitors.

Authors:  Adriana M das Neves; Gabriele A Berwaldt; Cinara T Avila; Taís B Goulart; Bruna C Moreira; Taís P Ferreira; Mayara S P Soares; Nathalia S Pedra; Luiza Spohr; Anita A A dE Souza; Roselia M Spanevello; Wilson Cunico
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

5.  Late-Stage Modification of Medicine: Pd-Catalyzed Direct Synthesis and Biological Evaluation of N-Aryltacrine Derivatives.

Authors:  Lin-Xi Wan; Yong-Qi Zhen; Zhen-Xiang He; Yang Zhang; Lan Zhang; Xiaohuan Li; Feng Gao; Xian-Li Zhou
Journal:  ACS Omega       Date:  2021-04-02

6.  3-Aryl-1-phenyl-1H-pyrazole derivatives as new multitarget directed ligands for the treatment of Alzheimer's disease, with acetylcholinesterase and monoamine oxidase inhibitory properties.

Authors:  Ashwani Kumar; Sandeep Jain; Milind Parle; Neelam Jain; Parvin Kumar
Journal:  EXCLI J       Date:  2013-12-13       Impact factor: 4.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.